Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban: A New Oral Factor Xa Inhibitor

(2010) Elisabeth Perzborn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans

(2009) D. Lang et al.   DRUG METABOLISM AND DISPOSITION

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

(2009) Alexander GG Turpie et al.   LANCET

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

The Primary and Secondary Prevention of Coronary Artery Disease

(2008) Richard C. Becker et al.   CHEST

Antithrombotic Therapy in Atrial Fibrillation

(2008) Daniel E. Singer et al.   CHEST

Antithrombotic Therapy for Venous Thromboembolic Disease

(2008) Clive Kearon et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Prevention of Venous Thromboembolism

(2008) William H. Geerts et al.   CHEST

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry

(2008) G. Rohde   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

(2008) Ajay K Kakkar et al.   LANCET

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

(2008) Bengt I. Eriksson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

(2008) Michael R. Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE